8 assets in Anal Canal Squamous Cell Carcinoma

Therapeutic assets addressing Anal Canal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Anal Canal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (64)
Fluorouracilum Anal Canal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	B (57)
Capecitabine Anal Canal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fludeoxyglucose Anal Canal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Anal Canal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Muamycin Anal Canal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer Anal Canal Squamous Cell Carcinoma	Bicara Therapeutics	P1	CC (43)
Pembrolizumab Anal Canal Squamous Cell Carcinoma	Bicara Therapeutics	P1	CC (43)